You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
|
|---|---|
| Published in |
Advances in Therapy, October 2013
|
| DOI | 10.1007/s12325-013-0060-1 |
| Pubmed ID | |
| Authors |
Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobagyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarina Petrakova, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo |
| Abstract |
Effective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 336 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | <1% |
| Ecuador | 2 | <1% |
| Chile | 1 | <1% |
| Portugal | 1 | <1% |
| Canada | 1 | <1% |
| Brazil | 1 | <1% |
| Japan | 1 | <1% |
| China | 1 | <1% |
| Unknown | 325 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 44 | 13% |
| Other | 43 | 13% |
| Student > Ph. D. Student | 37 | 11% |
| Student > Master | 37 | 11% |
| Student > Bachelor | 35 | 10% |
| Other | 55 | 16% |
| Unknown | 85 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 132 | 39% |
| Agricultural and Biological Sciences | 30 | 9% |
| Biochemistry, Genetics and Molecular Biology | 20 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 3% |
| Nursing and Health Professions | 7 | 2% |
| Other | 42 | 13% |
| Unknown | 96 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#1,090,882
of 23,351,247 outputs
Outputs from Advances in Therapy
#88
of 2,397 outputs
Outputs of similar age
#10,678
of 213,415 outputs
Outputs of similar age from Advances in Therapy
#1
of 17 outputs
Altmetric has tracked 23,351,247 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,397 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,415 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.